ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
暂无分享,去创建一个
Daniel F Hayes | R. Bast | M. Somerfield | N. Kemeny | D. Hayes | J. Jessup | G. Locker | Robert C Bast | J. Macdonald | Mark R Somerfield | Nancy Kemeny | Gershon Y Locker | Stanley Hamilton | Jules Harris | John M Jessup | John S Macdonald | J. Harris | S. Hamilton
[1] M. Rhyu,et al. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] D. Lane,et al. P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.
[3] A. Russo,et al. DNA Ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study , 2002, Journal of Cancer Research and Clinical Oncology.
[4] Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.
[5] F. Sinicrope,et al. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] Macdonald Js. Carcinoembryonic antigen screening: pros and cons. , 1999 .
[7] F. Momm,et al. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. , 2005, Anticancer research.
[8] Á. Kristjánsson,et al. Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. , 1999, Anticancer research.
[9] P. Johnston,et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. , 1992, Cancer research.
[10] V. Moreno,et al. Standardized approach for microsatellite instability detection in colorectal carcinomas. , 2000, Journal of the National Cancer Institute.
[11] Z. F. Liu,et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. , 1994, The New England journal of medicine.
[12] B. Iacopetta,et al. Prognostic Significance of Microsatellite Instability and Ki-ras Mutation Type in Stage II Colorectal Cancer , 2003, Oncology.
[13] J. Fleshman,et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Shung-Haur Yang,et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? , 2005, The Journal of surgical research.
[15] L. Johnson,et al. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. , 1985, Molecular pharmacology.
[16] H. Buhr,et al. Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? , 2004, Clinical & Experimental Metastasis.
[17] S. Sheen-Chen,et al. DNA index and S-phase fraction in curative resection of colorectal adenocarcinoma: Analysis of prognosis and current trends , 2002, World Journal of Surgery.
[18] F. Borchard,et al. The prognostic value of S-phase fraction in preoperative radiotherapy of rectal cancer. , 2001, Oncology reports.
[19] T R Fleming,et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. , 1993, JAMA.
[20] G. Peters,et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity , 2003, British Journal of Cancer.
[21] J. Bocsi,et al. Prognostic value of DNA ploidy status in patients with rectal cancer. , 2002, Anticancer research.
[22] Christophe Combescure,et al. Cost-effectiveness of Two Follow-up Strategies for Curative Resection of Colorectal Cancer: Comparative Study Using a Markov Model , 2004, World Journal of Surgery.
[23] D C Young,et al. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? , 1999, American journal of surgery.
[24] P. Quirke,et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study , 2002, The Lancet.
[25] L. Aaltonen,et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. , 1993, Cancer research.
[26] R. Lothe,et al. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Young Bae Kim,et al. Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer , 2005, Journal of Gastrointestinal Surgery.
[28] P. Bunn,et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. , 1998, Cancer research.
[29] L. D. Tin,et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. , 2001, The American journal of pathology.
[30] J. Folkman. What is the role of thymidine phosphorylase in tumor angiogenesis. , 1996, Journal of the National Cancer Institute.
[31] C. Behling,et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. , 2004, Gastroenterology.
[32] J. Nemunaitis,et al. Prognostic Role of K-ras in Patients with Progressive Colon Cancer Who Received Treatment with Marimastat (BB2516) , 2000, Cancer investigation.
[33] H. Ito,et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. , 1999, Cancer research.
[34] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[35] M. Leppert,et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[36] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[37] M. Loda,et al. The DCC protein and prognosis in colorectal cancer. , 1996, The New England journal of medicine.
[38] J. Arends,et al. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low‐turnover tumors with distinct clinical outcome , 2003, Cancer.
[39] R. Foà,et al. Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. , 1996, Cancer research.
[40] Jae Hyun Kim,et al. The clinicopathological significance of inferior mesenteric lymph node metastasis in colorectal cancer. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[41] J. L. García-Muñiz,et al. Cell cycle flow cytometric analysis in the diagnosis and management of colorectal carcinoma. , 1999, Analytical and quantitative cytology and histology.
[42] J. Palazzo,et al. Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. , 2000, Human pathology.
[43] J. M. Porcel,et al. Prognostic significance of DNA ploidy, S‐phase fraction, and P‐glycoprotein expression in colorectal cancer , 1999, Journal of surgical oncology.
[44] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Egger,et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials , 2002, BMJ : British Medical Journal.
[46] Tom Mala,et al. Hepatic resection for colorectal metastases: Can preoperative scoring predict patient outcome? , 2002, World Journal of Surgery.
[47] A. Goel,et al. Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients’ survival , 2004, Journal of Clinical Pathology.
[48] R. Costi,et al. Role of follow-up in management of local recurrences of colorectal cancer , 1998, Diseases of the colon and rectum.
[49] H. Sorbye,et al. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer , 2004, Acta oncologica.
[50] R. Gafà,et al. Sporadic colorectal adenocarcinomas with high‐frequency microsatellite instability , 2000, Cancer.
[51] Jen‐Kou Lin,et al. Loss of heterozygosity: an independent prognostic factor of colorectal cancer. , 2005, World journal of gastroenterology.
[52] W. Steinberg. The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.
[53] H. Sorbye,et al. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] K. Choe,et al. Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors , 1999, International Journal of Colorectal Disease.
[55] R. Lamerz,et al. Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin? , 2003, Oncology Research and Treatment.
[56] M. Duffy,et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. , 2003, European journal of cancer.
[57] J. Grem. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. , 2005, Seminars in oncology.
[58] J. Hainsworth,et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Sudhir Srivastava,et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.
[60] D. Schaid,et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. , 1999, Journal of the National Cancer Institute.
[61] Robert B. Diasio,et al. Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.
[62] G. Vreugdenhil,et al. Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma , 2001, Cancer.
[63] Daniel J Sargent,et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Jeffrey W. Clark,et al. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. , 2004, Clinical colorectal cancer.
[65] D. Birnbaum,et al. MSH2 and MLH1 immunodetection and the prognosis of colon cancer. , 2001, International journal of oncology.
[66] R. Houlston,et al. Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] T. Tsuruo,et al. Expression of platelet‐derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma , 2000, Cancer.
[68] H. Flyger,et al. Flow Cytometric Bivariate Analysis of DNA and Cytokeratin in Colorectal Cancer , 2002, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[69] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[70] C. Sherr. The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.
[71] R. Hofstra,et al. Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. , 2004, Clinical colorectal cancer.
[72] J. Rüschoff,et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. , 1997, Cancer research.
[73] R. Rosell,et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. , 1998, Gastroenterology.
[74] M. Tempero,et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.
[75] P. Simmonds,et al. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2000, BMJ : British Medical Journal.
[76] I. Frayling,et al. Systematic review of genetic influences on the prognosis of colorectal cancer , 2004, The British journal of surgery.
[77] K. Choe,et al. Prognostic Factors in 2230 Korean Colorectal Cancer Patients: Analysis of Consecutively Operated Cases , 1999, World Journal of Surgery.
[78] A. Norman,et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] R. Beart,et al. Follow-up of colorectal cancer , 1998, Diseases of the colon and rectum.
[80] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[81] A. B. Kuilenburg,et al. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. , 2004 .
[82] R. Rosell,et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer , 2001, Diseases of the colon and rectum.
[83] J. Daurès,et al. Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study , 2004, Journal of Gastrointestinal Surgery.
[84] K. Hoang-Xuan,et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites , 1998, Genes, chromosomes & cancer.
[85] I. D'Agnano,et al. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. , 2001, American journal of clinical pathology.
[86] H. Ueno,et al. Indicators for treatment strategies of colorectal liver metastases. , 2000, Annals of Surgery.
[87] R. Ward,et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] I. D'Agnano,et al. Evaluation of multiple bio‐pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl‐2 , 1999, International journal of cancer.
[89] A. Carothers,et al. Evidence for an age‐related influence of microsatellite instability on colorectal cancer survival , 2002, International journal of cancer.
[90] H. Hosogi,et al. Prognostic value of thymidine phosphorylase/platelet-derived endothelial cell growth factor in advanced colorectal cancer after surgery: evaluation with a new monoclonal antibody. , 2002, Surgery.
[91] J. Houghton,et al. CEA to detect recurrence of colon cancer. , 1994, JAMA.
[92] D. Tregouet,et al. Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy , 2004, Clinical Cancer Research.
[93] G. Peters,et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. , 2002, Biochimica et biophysica acta.
[94] R. Muraoka,et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. , 1997, Cancer letters.
[95] B. Iacopetta,et al. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. , 2001, Clinical colorectal cancer.
[96] M. Risio,et al. Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. , 2002, Cytometry.
[97] R. Gafà,et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer , 1998, International journal of cancer.
[98] S. Groshen,et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] T. Aikou,et al. The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas. , 1995, Cancer letters.
[100] E. Hitre,et al. Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients , 2004, International journal of cancer.
[101] S. Bull,et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.
[102] Hong Zhang,et al. Codon 201 polymorphism of DCC gene is a prognostic factor in patients with colorectal cancer. , 2003, Cancer detection and prevention.
[103] S. Clarke,et al. p53, Deleted in Colorectal Cancer Gene, and Thymidylate Synthase as Predictors of Histopathologic Response and Survival in Low, Locally Advanced Rectal Cancer Treated With Preoperative Adjuvant Therapy , 2003, Diseases of the colon and rectum.
[104] A. Carothers,et al. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. , 1996, Oncogene.
[105] P. Quirke,et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair , 1999, Gut.
[106] C. Purdie,et al. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma , 2000, Histopathology.
[107] A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.
[108] R. Herrmann,et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. , 2005, Oncology reports.
[109] H. Nielsen,et al. DNA ploidy in colorectal cancer, heterogeneity within and between tumors and relation to survival. , 1999, Cytometry.
[110] C. Earle,et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline , 2003, BMC Cancer.
[111] V. Zurawski,et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. , 1983, Clinical chemistry.
[112] P. Vihko,et al. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. , 1999, European journal of cancer.
[113] P. Vihko,et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers , 1999, British Journal of Cancer.
[114] F. Borchard,et al. Alteration of DNA ploidy status and cell proliferation induced by preoperative radiotherapy is a prognostic factor in rectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[115] H. Wieand,et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma , 1991, Cancer.
[116] T. Nagayasu,et al. Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. , 2004, Cancer letters.
[117] S N Thibodeau,et al. Microsatellite instability in cancer of the proximal colon. , 1993, Science.
[118] W. Hohenberger,et al. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer , 1998, Diseases of the colon and rectum.
[119] P. Catalano,et al. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. , 1998, Annals of surgery.
[120] M. Kohonen-Corish,et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] H. McLeod,et al. Molecular predictors of prognosis and response to therapy in colorectal cancer. , 2003, Cancer chemotherapy and biological response modifiers.
[122] Jukka-Pekka Mecklin,et al. SMAD4 as a Prognostic Marker in Colorectal Cancer , 2005, Clinical Cancer Research.
[123] Daniel J Sargent,et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.
[124] A. Jakobsen,et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] R. Gafà,et al. Immunohistochemical Pattern of MLH1/MSH2 Expression Is Related to Clinical and Pathological Features in Colorectal Adenocarcinomas with Microsatellite Instability , 2002, Modern Pathology.
[126] S. Groshen,et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer , 2004, British Journal of Cancer.
[127] K. Miyazono,et al. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. , 1992, Biochemical and biophysical research communications.
[128] E. Tiret,et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer , 2004, Gut.
[129] B. Nordlinger,et al. Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.
[130] J. Ko,et al. Genomic instability and alterations in Apc, Mcc and Dcc in Hong Kong patients with colorectal carcinoma , 1999, International journal of cancer.
[131] V. Catalano,et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[132] David K Whynes,et al. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer , 2004, BMJ : British Medical Journal.
[133] H. Zhang,et al. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] P J Catalano,et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.
[135] M. Jeffery,et al. Follow-up strategies for patients treated for non-metastatic colorectal cancer. , 2016, The Cochrane database of systematic reviews.
[136] L H Blumgart,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.
[137] E. Kay,et al. Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer , 2000, Gut.
[138] A. Matakidou,et al. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] Takaaki Masuda,et al. Localization of Thymidine Phosphorylase Expression in Colorectal Carcinoma Tissues by in situ RT-PCR Assay , 2002, Oncology.
[140] T. Urano,et al. Expression of DCC Protein in Colorectal Tumors and Its Relationship to Tumor Progression and Metastasis , 1999, Oncology.
[141] S Srivastava,et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.
[142] L. Påhlman,et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[143] J. Arnaud,et al. Carcinoembryonic antigen (CEA) in diagosis and prognosis of colorectal carcinoma , 1980, Diseases of the colon and rectum.
[144] B. Leggett,et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer , 2000, The British journal of surgery.
[145] T. Frebourg,et al. The evaluation of CA 19‐9 antigen level in the early detection of pancreatic cancer: A prospective study of 866 patients , 1988, Cancer.
[146] R. Gafà,et al. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma , 1998, Cancer.
[147] B. Iacopetta,et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[148] Hong Zhang,et al. Microsatellite instability and MBD4 mutation in unselected colorectal cancer. , 2003, Anticancer research.
[149] B. Leggett,et al. Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma , 2004, Gut.
[150] T. Sauerbruch,et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine , 2003, British Journal of Cancer.
[151] M. Hawn,et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. , 1998, Gastroenterology.
[152] D. Reding,et al. Cancer: beliefs and attitudes of migrant Latinos. , 1994, JAMA.
[153] L. Aaltonen,et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. , 2000, Gastroenterology.
[154] A. Shields,et al. Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study. , 2000, American journal of clinical oncology.
[155] A. Russo,et al. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[156] W. Scheithauer,et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.
[157] O. Nilsson,et al. Prediagnostic Levels of Carcinoembryonic Antigen and CA 242 in Colorectal Cancer: A Matched Case-Control Study , 2003, Diseases of the colon and rectum.
[158] M. Loda,et al. Evaluation of Microsatellite Instability and Updated Version Cited Articles Citing Articles E-mail Alerts Evaluation of Microsatellite Instability and Immunohistochemistry for the Prediction of Germ-line Msh2 and Mlh1 Mutations in Hereditary Nonpolyposis Colon Cancer Families , 2022 .
[159] J. Sulkes,et al. Deleted in Colorectal Cancer Protein Expression as a Possible Predictor of Response to Adjuvant Chemotherapy in Colorectal Cancer Patients , 2004, Diseases of the colon and rectum.
[160] R. Bast,et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[161] J. Nemunaitis,et al. Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). , 1997, American journal of clinical oncology.
[162] M. Herlyn,et al. Colorectal carcinoma antigens detected by hybridoma antibodies , 1979, Somatic cell genetics.
[163] D. Sargent,et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.